Located at the heart of the Pitié Salpêtrière hospital and supported by a scientific and clinical community of international stature, the ICAN IHU has forged numerous partnerships with pharmaceutical companies, from major groups to young biotechnology companies, as part of its research and development activities.
The ICAN teams are able to intervene at many stages in the development of a drug.
- Targeted advice and expertise on preclinical and clinical strategy in the field of cardiometabolic and nutritional pathologies (NASH, heart failure, diabetes and chronic wounds, rare diseases, etc.).
- Technology platforms offering scientific support and analysis in vitro, ex vivo and on biological samples collected as part of clinical investigations
- ICAN BioCell IPS, with a diversified range of differentiated cells derived from iPS cells (genomically edited or not) and customised services for cell differentiation and genomic editing (isogenic clones).
- ICAN BioCell Human Liver biology, access to liver tissue (fresh or frozen) taken during biopsies performed on patients with different pathologies and documented aetiologies.
- ICANalytics Omics lipidomics and metabolomics for OMICS analysis of human or animal biological samples.
- An ICAN Clinical Investigation platform specialising in the recruitment of patients suffering from cardiometabolic and nutritional pathologies, and supported by :
- An ICAN BioCollection Biological Resource Centre in the immediate vicinity (identification, processing, conservation) – ISO 9001 and NF S 96-900 certified
- A dedicated team (clinical research physician, IDE, expert TEC)
- Highly specialised analysis platforms (lipidomics, metabolomics).
- The first ICAN Imaging MRI platform dedicated to cardiovascular research in the Ile-de-France region, based on :
- World-class medical and scientific expertise (Cardiothoracic Imaging Centre, LIB Laboratory)
- An expert Corelab with proprietary analysis techniques
- Resources for identifying and validating new imaging biomarkers
